Lung infections associated with pneumonia, or cystic fibrosis caused by Pseudomonas aeruginosa or other bacteria, result in significant morbidity and mortality, in part owing to the development of multidrug resistance, also against last-resort antibiotics. Lytic bacteriophages (that is, viruses that specifically kill bacteria) can reduce lung-associated infections, yet their clinical use is hindered by difficulties in delivering active phages to the deep lung. Here, we show that phage-loaded polymeric microparticles deposit throughout the lung via dry powder inhalation and that they deliver active phages. Phage-loaded microparticles effectively reduced P. aeruginosa infections and the associated inflammation in wild-type and cystic fibrosis transmembrane-conductance-regulator knockout mice, and rescued the mice from pneumonia-associated death. These polymeric microparticles might constitute a clinically translatable therapy for eradicating hospital-acquired lung infections and infections associated with cystic fibrosis.
A pproximately 5.6 million cases of community-acquired pneumonia occur annually in the USA, and it is the most common cause of death from infectious disease 1 . Another 200,000 cases of healthcare-associated pneumonia result in 36,000 annual deaths in the USA 2 . The lungs of cystic fibrosis patients (~29,000 annually 3 ) also become colonized by pathogenic bacteria, resulting in chronic infection and inflammation 4 . Pseudomonas aeruginosa is the main causative agent of morbidity and mortality in lung infections 5, 6 . Antibiotic therapy is limited by dosing and multidrug resistance 4, 5, 7 , and even last-resort antimicrobials 8 are ineffective in eradicating infections [9] [10] [11] [12] .
Phages are promising agents for the treatment of bacterial infections due to their ability to infect and lyse bacteria, replicate and degrade biofilm matrix [13] [14] [15] [16] [17] . Because the mechanisms by which phages target bacteria are unrelated to the action of antibiotics, phage therapy is effective against multidrug-resistant bacteria 18, 19 . The use of mixtures of phages reduces the development of resistance against phage therapy 20 . Phages are specific to one, or a few, closely related target bacterial species, and do not infect the commensal microflora of the patient 21 , which can be severely perturbed by antibiotics. In addition, phages have been shown to produce less endotoxin upon bacterial lysis compared with antibiotics such as β -lactams 22 . Phages can be engineered to deliver biofilm-degrading enzymes, increase antibiotic efficacy or provide alternative antibacterial strategies [23] [24] [25] [26] . Recently, compassionate phage treatment of two patients with antibiotic-resistant bacteria in Europe and the USA has shown the translational potential, efficacy and safety of phage therapy 27, 28 . Several studies have shown the potential of phage therapy to reduce lung bacterial infections [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] . A recent study showed that phages and the immune system act synergistically to clear pathogenic lung infections 39 . However, the use of nebulizers or intranasal administration in these studies limits phage stability, clinical translation and patient compliance. To overcome these limitations, dry powder formulations of bacteriophages with or without excipients have also been tested [40] [41] [42] [43] [44] [45] . However, rapid loss of phage activity due to exposure to harsh fabrication conditions, lack of a suitable carrier for deep lung delivery and proof of efficacy in animal models are major challenges for clinical translation of phage therapy when used without suitable delivery vehicles. Here, we describe engineered phage-loaded microparticles (phage-MPs) for pulmonary administration via dry powder inhalation to deliver therapeutic doses of active phages to the site of infection, and demonstrate significant reductions in bacterial counts and enhanced survival of the host. This therapeutic formulation is stable at room temperature and can be translated to conventional inhalers for ease of administration and increased patient compliance.
For pulmonary delivery, particles must have an aerodynamic diameter (d aer ) of ~1-5 µ m for efficient deposition to the deep lung 46 . The d aer is related to the physical diameter d and density ρ of the particle ( ρ = d d aer ). For polymeric particles (ρ ~ 1.0 g cm −3 ), the particle diameter should be ~1-5 µ m. However, at this size range, alveolar macrophages rapidly clear particles 47 , thereby reducing the therapeutic effect. To avoid clearance, the particle diameter should exceed 5 µ m-beyond the uptake capability of alveolar macrophages. This can be accomplished by using larger particles that are porous to reduce their density. Furthermore, large particles have lower aggregation compared with smaller particles and allow for improved aerosolization for dry powder formulations 46 . Such porous particles have been used for the delivery of various therapeutics [48] [49] [50] [51] [52] , but their use for delivery of phages has not been reported.
Results
Phage-MPs effectively kill bacteria. We prepared hollow poly(lactic-co-glycolic acid) (PLGA) MPs via water-oil-water double emulsion (Fig. 1a,b ). Porous particles were generated by including ammonium bicarbonate (ABC) as an effervescent in the inner aqueous phase 53 . By tuning the processing parameters, we generated highly porous MPs of the appropriate size (d = 8.0 ± 4.5 µ m) and density (~0.3 g cm −3 ) to yield a d aer of 2-5 µ m (Fig. 1c,d and Supplementary Fig. 1 ).
Several lytic phages against P. aeruginosa ( Supplementary  Table 1 ) were amplified, purified by liquid chromatography and loaded onto MPs by incubation in phage-containing solution. In this system, the phages are not encapsulated within the MPs, but are deposited on the surface of the MPs after the MPs are synthesized. This approach minimizes any loss in phage activity from the solvents used for MP fabrication, and no loss of phage activity was observed upon loading. MPs were loaded with a defined mixture of three to five different phages to increase the infectivity and bactericidal activity and reduce the probability of development of resistance. Porous MPs provide a large surface area for phage adsorption, and phage loading was 2.6 ± 0.2 plaque-forming units (p.f.u.) per particle or ~2.6 × 10 6 p.f.u. mg −1 MPs. Endotoxin levels for the phage-MP formulation were 0.078 ± 0.003 EU (endotoxin units) mg −1 ; that is, two orders of magnitude below the 20 EU per device limit stipulated by the Food and Drug Administration. As expected, these larger porous phage-MPs (8.0 µ m diameter) exhibited reduced internalization by macrophages compared with nonporous, smaller (1 µ m diameter) phage particles ( Supplementary  Fig. 2 ). To test the bactericidal activity of phage-loaded MPs, phage-MPs or empty MPs were plated onto lawns of P. aeruginosa expressing green fluorescent protein (PAO1-GFP) and incubated for 16 h at 37 °C. Efficient lysis of bacteria was observed around phage-MPs, as shown by zones devoid of fluorescence, whereas control MPs had no effect on PAO1-GFP levels (Fig. 1e,f) . Notably, the killing zone for phage-MPs extended beyond the particle area, indicating that phages propagated radially outwards from the MPs, and showing that phages delivered from MPs can infect, replicate, propagate and kill target bacteria beyond those in direct contact with the MPs. Next, we tested whether phage-MPs can infect and kill bacteria in synthetic sputum, to model the viscous mucus in the lung. Synthetic sputum was prepared 54 , and growth curves in the presence and absence of phage-MPs were monitored. No growth was observed in the presence of phage-MPs, while bacteria rapidly grew under the control conditions ( Supplementary Fig. 3 ). This result shows that phage-MPs can infect and effectively kill bacteria in viscous model sputum. A major challenge for the treatment of lung-associated infections is the formation of biofilms by P. aeruginosa 5, 55 . We tested the ability of phage-MPs to lyse bacterial biofilms. Treatment with phage-MPs resulted in effective killing of P. aeruginosa in biofilms ( Fig. 2 ).
We prepared dry powder formulations of phage-MPs by lyophilizing phage-loaded MPs suspended in lactose. Dry powder formulations of phage-MPs were tested for 16 d and only showed a slight loss of titre when stored at room temperature ( Supplementary Fig. 4 ). Such dry powder formulations can be easily administered to patients using inhalers, have a long shelf life and increase patient compliance. Next, we performed studies to determine the release kinetics of phages from dry powder MP formulations. An initial burst release of approximately 10-15% of loaded phages was observed followed by very slow release ( Supplementary Fig. 5 ), consistent with stable deposition of phages on the particle surface and slow degradation of the PLGA polymer used 56 . Attempts to characterize longterm release kinetics were not successful as this requires incubation in aqueous buffer and there is loss of phage activity over time in an aqueous environment at 37 °C.
Inhaled phage-MPs distribute throughout the murine lung.
For delivery to the mouse lung, lyophilized powder was mixed with inhalation grade lactose, and aerosolized using a mouse dry powder insufflator. First, we evaluated the safety and clearance of MPs delivered via endotracheal intubation. Intravital imaging with near-infrared dye-labelled MPs showed that MPs were cleared from the lungs of healthy mice within 18 h ( Supplementary  Fig. 6 ). Histological sections at 1 and 7 d post-delivery showed minimal leukocyte infiltration and normal lung tissue structure ( Supplementary Fig. 7 ). No differences were observed in tissue histology between lungs receiving MP-lactose powder and control lactose powder (no MPs). Next, we evaluated the distribution of fluorescent MP-lactose dry powder after insufflation via endotracheal intubation. Organs were explanted immediately after delivery and imaged for total fluorescence. All fluorescence was localized to the lungs (Fig. 3a,b ), and fluorescent MPs were found throughout the lung tissue ( Fig. 3c ). These results show targeting of MPs to the lung as well as distribution throughout the lung via dry powder inhalation. To quantify phage delivery, we delivered phage-MPs or phages alone (no MPs) via insufflation. High phage titres (10 4 -10 5 p.f.u. mg -1 of tissue) were recovered from the lungs treated with phage-MPs, whereas no phages were recovered from the lungs receiving free phages ( Supplementary Fig. 8a ). These results show that using MPs significantly enhances the delivery of active phages to the lungs. We also examined the deep lung distribution of phage-loaded porous and non-porous MPs. Phages were delivered as previously described and the deep lungs were harvested. Significantly higher deposition of phages in the deep lung was observed for delivery with porous MPs compared with non-porous MPs ( Supplementary Fig. 8b ).
An attractive attribute of phages compared with other antimicrobials is the ability to persist and replicate at infection sites until the pathogen is cleared. We established an acute model of lung infection using different PAO1-GFP doses, and evaluated the persistence of bacteria at 24 h post-inoculation in healthy mice ( Supplementary  Fig. 9 ). A dose of 5 × 10 6 colony-forming units (c.f.u.) of PAO1-GFP was selected for the subsequent experiments. Phage-MPs were delivered to both control and PAO1-GFP-infected lungs, and 3 orders of magnitude higher phage counts were detected in PAO1-GFP-infected lungs compared with control (uninfected) lungs at 0 h ( Supplementary Fig. 8 ) and 18 h post-delivery ( Supplementary  Fig. 10 ). This result shows that phages delivered to the lungs via MPs can infect and amplify in vivo only in the presence of target bacteria.
Phage-MP treatment clears infection from mice lungs.
We tested the ability of phage-MPs to reduce acute bacterial lung infections in wild-type mice. Phage-MPs and controls were delivered via insufflation to PAO1-GFP-infected mice, and the lungs were assayed for bacterial and phage counts after 24 h ( Fig. 4a,b ). Delivery of phage-MPs reduced bacterial counts by an order of magnitude (P = 0.0203) compared with the bacteria + phages group, whereas free phage delivery (same dose as the phage-MPs) had no effect on bacterial counts (P > 0.12) compared with animals treated with bacteria alone. Counts of phages active against P. aeruginosa were elevated for both free phages and phage-MPs. Importantly, treatment of infected mice with phage-MPs rescued 100% of subjects from pneumonia-associated death compared with only 13% survival for untreated mice over 6 d ( Fig. 4c ). These results show that phageloaded MPs effectively reduce P. aeruginosa lung infections in wildtype mice and rescue mice from pneumonia-associated death. We also examined the effects of phage-MPs on P. aeruginosa infection in the gut-corrected cystic fibrosis transmembraneconductance-regulator (CFTR) knockout (CFKO) mouse 57 . This model mimics several aspects of the cystic fibrosis human condition, including increased pathogenesis from P. aeruginosa lung infections 58, 59 . A dosing study with PAO1-GFP identified a suitable dose to obtain an acute infection ( Supplementary Fig. 11 ). A dose of 2 × 10 6 c.f.u. PAO1-GFP was used. This dose was lower than that needed for wild-type mice in the earlier experiment, suggesting that CFKO mice have reduced capacity to clear bacteria from the lungs. PAO1-GFP infection and delivery of phage-MPs were performed as described earlier. The delivery of phage-MPs dramatically reduced bacterial counts in the lungs by three orders of magnitude, near the assay detection limit ( Fig. 5a,b ). In contrast with wild-type mice, treatment with phages alone also reduced the bacterial burden in the lung of CFKO mice, but significant levels of bacteria were still present. This modest efficacy could be the result of a higher phageto-bacteria ratio as the bacteria dose delivered to CFKO mice was lower than that for wild-type mice. Nevertheless, when comparing free phages with phage-MPs, the use of phage-MPs resulted in ~1.5 orders of magnitude lower bacteria counts compared with free phages. Phages were detected in the lung tissue for both phage-MPs and free phages. We assessed bacteria levels in the liver of these mice to determine whether the infection spread to other organs. Remarkably, no mice treated with phage-MPs showed any detectable bacteria in the liver (0 out of 7 mice), whereas > 70% of untreated mice (5 out of 6 mice) or mice treated with free phages (5 out of 7 mice) had measurable levels of bacteria in the liver (Fig. 5c ). Histological analyses revealed massive infiltration of host immune cells in untreated infected lungs ( Fig. 5d ). Infected mice treated with free phages displayed moderate levels of cell infiltration ( Fig. 5e ). Importantly, infected mice treated with phage-MPs had low levels of immune cell infiltration ( Fig. 5e ), indicating that this treatment reduces the bacterial load as well as infection-associated inflammation. Immunostaining analysis on lung sections confirmed these observations ( Supplementary Fig. 12 ).
Phage-MPs kill clinical bacterial strains.
To evaluate the clinical potential of the phage-MP formulation, we screened phage-MPs against clinical strains of bacteria isolated from hospital-associated lung infections and cystic fibrosis patients. The phage-MP formulation was effective against all acute-infection clinical strains and five out of six clinical strains from cystic fibrosis patients tested in vitro, including antibiotic-resistant strains (CFBR 337 and CFBR 505 are tobramycin-resistant) (Supplementary Table 2 ). We then evaluated the in vivo efficacy of phage-MPs against PA103 (a historical strain derived from the sputum of a patient 60 ) in mice. A dosing study with PA103 identified a dose (1.6 × 10 5 c.f.u.) suitable to obtain an acute infection in wild-type mice ( Supplementary Fig. 13 ). To achieve high phage titres against PA103, our phage library was screened against PA103, and three different phages were chosen and loaded onto the MPs ( Supplementary Table 3 ). PA103 infection and delivery of phage-MPs were performed as described earlier. The delivery of phage-MPs effectively reduced bacterial counts in the lungs, showing efficacy against a patient-derived bacterial strain ( Fig. 6a,b ). To test whether direct deposition of phages onto MPs (instead of simple co-delivery of phages and MPs) is required for effective in vivo bacterial clearance, a physical mixture of phages and unloaded MPs with inhalation grade lactose was evaluated. In contrast with effective bacteria reduction with phage-MPs, a physical mixture of phages and unloaded MPs did not reduce the bacteria load in the lung (Fig. 6a) , showing that only phages that are directly deposited on the MPs kill bacteria in vivo. We also tested 10 bacterial colonies recovered from phage-MP-treated mice for the development of phage resistance against the stock phage mixture during the 18 h of incubation in the mouse lung. All of the recovered colonies were still sensitive to phage-MPs.
Phage-MPs are effective against infection from multiple strains.
Another challenge for antimicrobial therapy against P. aeruginosa infection is the presence of distinct populations and their diversification in the patient lung 61, 62 . To test whether phage-MP treatment can be effective against infection consisting of multiple strains of bacteria, we infected mice with a mixture of PAO1-GFP (2.5 × 10 6 c.f.u.) and PA103 (8 × 10 4 c.f.u.) strains. Phages listed in Supplementary  Tables 1 and 3 were mixed and loaded on MPs. Treatment with phage-MPs effectively reduced total bacterial counts in the lungs, showing efficacy against infections comprising simultaneous infection by two strains of P. aeruginosa (Fig. 6c ). We also tested ten bacterial colonies of each strain recovered from phage-MP-treated mice for the development of phage resistance against the stock phage mixture, and all recovered bacteria were still susceptible to phage-MP treatment. Finally, to evaluate the efficacy of phage therapy after repeated administration, we delivered empty MPs and phage-MPs in naïve mice. After 21 d, mice in both groups were infected with PA103, and phage-MP treatment was performed. Pre-exposure with phage-MPs did not affect the efficacy of treatment compared with the no pre-exposure control group (Fig. 7 ). Furthermore, no antibody titres in the blood (0/5 mice) were detected against phages at any time points tested (days 0, 21 and 22) . This result indicates that preexposure to phage-MPs via dry powder delivery did not reduce its functional performance.
Discussion
We demonstrate that phages can be effectively delivered to lungs using polymeric MPs, and that MP-delivered phages retain their activity to kill host bacteria. Phage-loaded MPs significantly reduced P. aeruginosa infections and associated inflammation in healthy mice and mice with cystic fibrosis, and rescued mice from pneumonia-associated death. Importantly, phage-MPs were effective against clinically derived strains, including antibiotic-resistant strains, as well as lung infections caused by two strains of bacteria. The acute-infection murine model used in our study lacks biofilm formation, mucus plugging, and genetic, phenotypic and spatial diversification of bacterial strains 61, 62 . Nonetheless, we show that phage-MPs were effective against clinically derived strains from acute infections and cystic fibrosis patients, and were able to kill bacteria growing in biofilms. Interestingly, when we delivered free phages to the healthy lung as a dry powder formulation and immediately assayed the lungs, we did not recover any active phages from the lung homogenate. This result is in contrast with previous studies [29] [30] [31] [32] [33] [34] , where free phage administration was shown to be effective against bacterial infections. This discrepancy could be due to differences in the mode of administration. All previous reports have used intranasal administration of phages in liquid, whereas we used a dry powder formulation of free phages. Another reason for this discrepancy could be that the titres delivered for free phages in our experiment (~10 6 p.f.u. mg -1 MPs) were significantly lower compared with previous reports (10 9 -10 10 p.f.u.). For the acute lung infection model in healthy mice and mice with cystic fibrosis examined in this study, phage-only treatment had modest efficacy in reducing the bacterial burden, even though active phages were recovered. In contrast, phage-MP treatment significantly reduced the bacterial burden, rescued mice from pneumonia-associated death and prevented bacterial colonization of the liver. We attribute this enhanced bactericidal efficacy for phage-MPs to the improved lung delivery afforded by the engineered MPs. Indeed, direct deposition of phages onto the MPs was required for effective in vivo bactericidal activity, as physical mixtures of phages and unloaded MPs had no effects. Bacteria recovered from the lungs of infected mice treated with phage-MPs were tested for their susceptibility against phage-MPs, and all test samples were still susceptible to phage infection and lysis. Although this result suggests a lack of phage resistance, more in-depth analysis in future studies is necessary. The present analysis focused on acute lung infection in healthy and cystic fibrosis murine models; future studies will test the efficacy of dry powder inhalation-based phage-MP therapy in more challenging chronic infection models. Phage therapy (via the intranasal route) has recently been shown to be effective against P. aeruginosa chronic infections 63 . The mice used in our experiments are expected to have several commensal bacterial species 64, 65 . Although we did not investigate the effect of phage treatment on other resident species of bacteria in mice lungs, our treatment was able to reduce the counts of pathogenic bacteria from the whole lung microbiome. Even though phages are highly specific to their host species, it will be important for future studies to evaluate the effect of phage treatment on the entire lung microbiome-especially how targeting a single organism impacts the remaining organisms in that community. A concern with phage therapy is that immune responses to the phages could result in elevated, undesirable inflammation and immune reactions that could reduce phage activity. Indeed, intraperitoneal administration of phages resulted in high-titre phage-specific antibodies in the blood 18 . In the present study, we did not observe any adverse or elevated inflammation in response to phage-MP treatment, nor the presence of phage-specific antibodies in the blood of treated mice.
In addition, pre-exposure of phage-MPs did not result in a reduction of its functional efficacy to subsequent bacterial challenge. These differences in host responses to phages and phage activity could be due to differences in the route of administration (intraperitoneal versus lung insufflation), phage dose delivered and/or use of MPs as phage delivery carriers. Further studies are needed to establish whether adverse immune responses, antibody production and/or a reduction in phage efficacy arise when phage-MPs are administered several times. Nevertheless, dry formulations of phage-MPs represent a promising alternative to antibiotic regimens, which are severely limited by ineffective dosing and the emergence of antibiotic resistance. The ability to deliver active phages using engineered biomaterials as dry powder formulations provides significant clinical benefits for lung infections, including longer drug stability, ease of administration with fewer side effects and increased patient compliance.
Methods
PLGA MPs. MPs were prepared by double emulsion of water in oil in water. Some 200 mg PLGA (RG503H; Sigma-Aldrich) was dissolved in 7 ml dichloromethane (DCM). ABC (Sigma-Aldrich) was used as an effervescent to create porous MPs in 1 ml of internal aqueous phase at 4% w/v. The concentration of ABC can be varied to tune the porosity and density of MPs. The solution was homogenized at 3,000 r.p.m. for 2 min and then mixed with 50 ml of 1% poly(vinyl alcohol) (PVA) (Sigma-Aldrich) and homogenized for 2 min. The final emulsion was added to 100 ml 1% PVA and stirred to evaporate all the DCM for 5 h. MPs were washed with deionized water 4 times to remove the PVA and free polymer and lyophilized for 16 h. Fluorescent MPs were prepared by adding 1,1′ -dioctadecyl-3,3,3′ , 3′ -tetramethylindocarbocyanine perchlorate (DiI) or 1,1′ -dioctadecyl-3,3,3′ , 3′ -tetramethylindotricarbocyanine iodide (DiR) dye (Thermo Scientific) (5 mg dye per 200 mg PLGA) in DCM.
Particle size and density. The size distribution of the MPs was characterized using a Multisizer 3 Coulter counter. To determine the density of the MPs, 1.0 mg lyophilized MPs were suspended and counted in the Coulter counter. The total volume of MPs in 1.0 mg was calculated using the average diameter obtained from the Coulter counter. Density was calculated by theoretical calculation based on mass = density × volume.
Scanning electron microscopy of MPs.
For scanning electron microscopy (LEO 1550), an MP suspension (5 μ l of 1 mg ml −1 solution) was dispensed on a scanning electron microscopy stub, air dried for 2 h at room temperature and sputter coated with 5 nm of gold to make the sample conductive. Imaging was performed with a 5 KeV electron beam. in the lung homogenate were quantified. Data were collected on male wild-type C57BL/6 mice. One-way ANOVAs followed by Tukey's multiple comparison tests were used to detect statistical differences.
Fluorescent plaque imaging. PLGA MPs were loaded with phage and washed, and various dilutions were plated with PAO1-GFP on trypticase soy agar plates. Plates were incubated for 18 h at 37 °C and imaged on a Nikon C2 laser scanning confocal microscope with a 10× objective. PAO1-GFP was excited with a 405 nm laser and emitted light was collected through a 485/35 nm filter cube. Particles were excited with a 561 nm laser and emitted light was collected through a 595/50 nm filter cube. Tables 1 and 3 ; described previously 66 ) were amplified in liquid culture of 25% trypticase soy broth (TSB; Becton Dickinson). Phages were added to an exponentially growing culture of their respective bacterial host at 10 7 -10 8 c.f.u. ml −1 and incubated at 37 °C until lysis occurred (the culture visibly cleared). The resulting lysate was clarified further by adding 2% v/v chloroform, decanting centrifugation and filtrating the supernatant (0.2 µ m pore membrane).
Phage amplification. Phages (Supplementary
Phage purification. For phage purification, an anion-exchange chromatography column, CIM QA-8f ml Tube Column (BIA Separations), was used 67 . The column was attached to an AKTA fast protein liquid chromatography system (GE Healthcare) with a P900 pump system, and analysed with UNICORN 5.01 software. Phage lysate was diluted 50% with Tris buffer (40 mM Tris-HCl, pH 7.5) and loaded onto the column. Phages were then washed with Tris buffer (20 mM Tris-HCl, pH 7.5). For elution, a gradient was used by linearly mixing an increasing amount of 1.5 M NaCl, 20 mM Tris-HCl solution with 20 mM Tris-HCl buffer, and collected using a fraction collector. Phages were then dialysed with 0.1 M phosphate buffer supplemented with 2 mM MgSO 4 , passed through an endotoxin removal column and stored at 4 °C.
Active phage counts. Preparations were counted for active phages with plaque assays, using the traditional top agar overlay method 68 .
Phage loading on particles. MPs (4 mg) were suspended in a solution of phage mixture (~10 10 -10 11 phages ml −1 ) for 4 h with mild shaking. MPs were then washed three times with phosphate buffered saline (PBS). To determine phage loading levels on MPs, Φ Paer14 was loaded on the particles. Some 500 µ l of phage-MP and 500 µ l of chloroform were mixed for 20 min at room temperature to dissolve the PLGA. Free phage standards were run in parallel to determine the effects of chloroform on phage stability. Samples were centrifuged at 500g for 5 min to separate the organic and aqueous phases. Phage titres were performed on the aqueous phase. Particles were enumerated using a haemocytometer, and the number of phages per particles was calculated using the following the formula ((p.f.u. ml -1 ) × adjustment)/(particles ml -1 ), where the adjustment was determined by dividing the p.f.u. ml -1 of a phage standard by the p.f.u. ml -1 of the same standard exposed to chloroform for 20 min, as described above.
Dry powder preparation.
To prepare dry powder formulations, 4.0 mg of washed phage-MPs was suspended in 100 µ l solution of lactose (40 mg ml −1 ), resulting in a 1:1 ratio of particle:lactose, and lyophilized for 24 h. For the free phage dry powder formulation, phage titres were adjusted to the amounts of phages loaded on the MPs, suspended in 100 µ l solution of lactose (40 mg ml −1 ), resulting in a 1:1 ratio of particle:lactose, and lyophilized for 24 h. For stability testing, the dry powder mixture was stored at room temperature. Phage activity in the lyophilized powder was tested using the phage enumeration method described above on PA103. For in vivo work, lyophilized powder was mixed with 32 mg inhalation grade lactose (Respitose ML006; DFE Pharma), resulting in a 1:10 final ratio of particle:lactose. Powder was vortexed for 1 h at room temperature (VWR Mini Vortex Mixer; speed 7).
Phage-MP endotoxin quantification.
Lyophylized phage-MPs (0.5 mg) were washed by centrifugation in 40 ml of endotoxin-free water as per the FDA 'Guidance for Industry: Pyrogen and Endotoxins Testing' (www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ucm314718). Endotoxin was then quantified using a LAL Chromogenic Endotoxin Quantification Kit (Thermo Scientific) per the manufacturer's instructions.
Phage release from particles. Lyophilized phage-MPs were suspended in PBS and total p.f.u. were enumerated using the top agar overlay method. For phage release, phage-MPs were centrifuged at 500g for 5 min and the supernatant was assayed for p.f.u.
In vitro phage-MP phagocytosis. RAW264.7 macrophages were cultured in Dulbecco's modified Eagle medium supplemented with 4.5 g l -1 glucose and 10% foetal bovine serum in 24-well plates at 37 °C and 5.0% CO 2 in a humidified incubator. Fluorescent DiI-labelled particles were synthesized as described above. Smaller particles (0.94 ± 0.59 µ m) were generated by modifying the homogenization speed to 10,000 r.p.m. The PAO1 phage mixture was loaded on the MPs. Following loading, MPs of different sizes were added to tissue culture media at a concentration of 0.25 mg ml -1 and incubated with cells for 2 h. Cells were washed 5 times with PBS to remove excess particles, fixed, and stained with 4′ ,6-diamidino-2-phenylindole (DAPI) and Phalloidin-iFluor 488 (Abcam). Samples were imaged using a Nikon C2 laser scanning confocal microscope through a 10× objective. Three images of each well were acquired. Macrophage phagocytosis was evaluated in ImageJ by performing maximum intensity Z projections and thresholding the green (phalloidin) channel, followed by particle tracking analysis (at a minimum size of 20 pixels) to identify the cell border. Fluorescent blue (DAPI) and red (MP) images were then overlaid, and MPs falling inside cell borders containing a nucleus were counted as having been phagocytosed by cells. The total number of cells within an image field was quantified using the ComDet (version 0.3.6) plugin. The percentage of phagocytic cells was computed by dividing the number of phagocytic cells in an image by the total number of cells in the image.
In vitro growth of bacteria in synthetic cystic fibrosis sputum. Synthetic cystic fibrosis sputum was prepared as described previously 54 . A 50 µ l culture of PA103 was grown for 16 h in synthetic cystic fibrosis sputum and used to inoculate 3 ml of the sputum medium in the presence or absence of 0.1 mg of phage-MPs. Cultures were grown at 37 °C and regular optical density measurements were taken to monitor the bacterial growth.
In vitro activity of phage-MPs against bacterial biofilms. To form biofilms, 5 µ l culture of PA103 was grown for 16 h in 25% TSB, used to inoculate 500 µ l of 25% TSB in each well of a 48-well plate and allowed to grow for 24 h at 37 °C. Biofilms were carefully washed with PBS and incubated with 0.01 mg ml -1 of MPs or phage-MPs for 18 h at 37 °C in 25% TSB. Biofilms were then washed and stained with LIVE/DEAD BacLight (Thermo Scientific) (3 μ l dye mixture per ml of bacterial medium) and imaged on a Nikon C2 laser scanning confocal microscope with a 10× objective. SYTO 9 (live cell stain) was excited with a 488 nm laser and emitted light was collected through a 525/50 nm filter cube. Propidium iodide (to stain cells with a compromised membrane that are considered dead or dying) was excited with 561 nm, and emitted light was collected through a 595/50 nm filter cube. To prevent bleed-through of the fluorescence signal, each fluorophore was excited, and emitted light was collected in series. The image from each well was analysed for the mean pixel intensity in live and dead channels using ImageJ software (NIH). The ratio of the mean intensity of live and dead cells was plotted.
In vitro activity of phage-MPs against clinical strains of bacteria.
To test the activity of phages loaded on the MPs, a 5 µ l drop of phage-MPs at 4 mg ml −1 was spotted onto a lawn of respective bacteria (Supplementary Table 2 ) and allowed to grow for 16 h at 37 °C. The formulation was defined as effective if the spot was visually cleared of any bacterial growth after 16 h of incubation.
Bacterial inoculum preparation. Colonies were resuspended in sterile PBS and the optical density was measured at 600 nm. For each optical density value, serial dilutions were plated on ampicillin-fortified (100 µ g ml −1 ) lysogeny broth agar plates for 24 h at 37 °C with atmospheric CO 2 . Colonies were counted and plotted against their respective initial optical density values. Bacterial challenges were performed with P. aeruginosa expressing green fluorescence protein (PAO1-GFP) or the clinically derived bacteria strain PA103 (America Type Culture Collection 29260). Bacteria were grown on ampicillin-fortified (100 µ g ml −1 ) lysogeny broth agar plates for 24 h at 37 °C with atmospheric CO 2 . Colonies were removed from the plate with an inoculation loop and resuspended in sterile PBS. Optical density measurements were taken of the solution and adjusted to achieve the required concentration based on a previously determined optical density growth curve for the respective bacteria.
Care and use of mice. All experiments were conducted in accordance with Institutional Animal Care and Use Committee-approved protocols at the Georgia Institute of Technology and Emory University. All animals were housed in specific pathogen-free housing with 12 h light and 12 h dark cycles and received food and water ad libitum. The CFKO mouse Cftrtm1Unc Tg(FABPCFTR)-1Jaw/ J 57 (C57BL/6 and FVB/Nj background) was used in some experiments. These CFKO mice are heterozygous for whole-body knockout of murine CFTR and have human CFTR expression regulated by expression of the fatty-acid-binding protein promoter. As such, expression of human CFTR is limited to the small and large intestine with subsequent improved viability and no dietary restrictions or special dietary supplementation compared with the whole-body knockout. C57BL/6 or wild-type littermates of CFKO mice were used as wild-type mice. Both female and male mice were used (randomized) for experiments involving CFKO mice and littermates. Only male mice were used for experiments involving C57BL/6 mice. All animals were used within the age range of 8-14a weeks.
In vivo bacterial challenge. Mice were placed under general anaesthesia with an intraperitoneal injection of ketamine and xylazine (100 mg kg −1 and 10 mg kg −1 , respectively). Dry powder phage-MPs (1.0 mg) were delivered to the lungs via a Dry Powder Insufflator (model DP-4M; Penn-Century). Bacteria were inoculated using a MicroSprayer Syringe Assembly (model MSA-250-M; Penn-Century) by injecting 50 µ l of the appropriate optical density of bacterial solution through an endotracheal tube. Successful lung delivery was confirmed by a change in the respiratory status of the animal. Mice were placed under a warming lamp and allowed to recover from general anaesthesia. Some 18-24 h after the intratracheal instillation of bacteria, mice were euthanized by intraperitoneal overdose of pentobarbital (150 mg kg −1 ; Euthasol) for organ collection. For assaying phage counts in tissues, organs were explanted, weighed and homogenized in sterile PBS. Homogenates were serially diluted and cultured on lysogeny broth agar plates fortified with ampicillin (100 µ g ml −1 ) to select for PAO1-GFP or PA103. Homogenate serial dilutions were also titred for phages on the inoculating bacteria-either PAO1-GFP or PA103. Culture plates were incubated at 37 °C under atmospheric CO 2 , and bacterial colonies or plaques were counted after 16 h incubation. For mixed infections, colony morphology was used to distinguish the different strains of bacteria. The detection limit of colonies was defined as ten colonies in undiluted lung homogenate plates to prevent counting any lung tissue fragments as false positive.
Immune response against phages. Mice were given no treatment or dry powder formulations of phage-MPs or empty MPs. After 21 d, all mice were challenged with bacteria and either treated with phage-MPs or left untreated. Mice were euthanized after 18 h and assayed for phages and bacteria as described above. For all time points (days 0, 21 and 22), serum was collected via a cheek bleed. To assay for the presence of antibodies, phages were incubated in a 96-well plate for 1 h and washed multiple times with 0.05% v/v Triton X-100 in PBS. Samples were then incubated in 1% w/v casein blocker (Life Technologies) and treated with serum collected at each time point (diluted 1:10 in PBS) for 1 h. Wells were then incubated with alkaline-phosphatase-conjugated anti-mouse antibody (1 µ g ml -1 ) (715-055-151; Jackson ImmunoResearch). Following several washes, samples were incubated with 5-methyl umbelliferyl phosphate substrate (60 µ g ml -1 ) and fluorescence read at an excitation of 360 nm and an emission of 465 nm on a HTS 7000 Plus plate reader (Perkin Elmer).
Phage resistance. Individual colonies recovered from phage-MP-treated mice were suspended in PBS and plated on trypticase soy agar plates. A 10 µ l drop of the original phage mixture was spotted on the soft agar seeded with the appropriate host strain and allowed to grow for 16 h at 37 °C. Bacteria were defined as susceptible to phage mixture if the spot was cleared of any bacterial growth after incubation for 16 h.
Live animal imaging. Hair at the dorsum was removed and the animal was imaged using 750 nm excitation and 800 nm emission with an IVIS SpectrumCT system (Perkin Elmer) or a Fluorescence Molecular Tomography imaging system (Perkin Elmer). The fluorescence intensity was analysed using the manufacturer's software.
Lung histology. Lungs were harvested at necropsy, fixed in 10% neutral buffered formalin for 16 h, washed with PBS, dehydrated in 70% ethanol and embedded in paraffin. Sections (5 µ m) were cut using a Microm 355 H microtome and stained with haematoxylin and eosin. For immunohistochemistry, sections were treated with 0.05% trypsin for 10 min at 37 °C, blocked with goat serum and stained with rabbit anti-P. aeruginosa antibody (ab68538; Abcam). Slides were washed, blocked with goat serum and then stained with AlexaFluor 555-conjugated goat anti-rabbit IgG (A21428; Thermo Scientific) and DAPI. For the lung cryosection images, fluorescent MPs were delivered and mice were immediately euthanized. Lungs were harvested, mounted in optimal cutting temperature (OCT) embedding compound and flash frozen in liquid nitrogen. Sections (10-20 µ m thick) were cut using a cryostat (Leica CM3050 S). The slides were dried at room temperature for 30 min, washed with PBS and stained with DAPI.
Statistical analysis.
All experiments were performed on independent biological replicates. The sample sizes for each experimental group and the statistical tests used to determine significant differences among groups are reported in the appropriate figure legends. Non-parametric tests were used if the data did not meet the assumptions of t-tests or analysis of variance (ANOVA). For the in vitro experiments, sample size was not predetermined, and all samples were included in the analysis. For the animal experiments, sample size was determined based on power calculations to detect 20% differences among the means using variances from previous/pilot experiments. All animals were used for analysis unless the mice died or had to be euthanized because of pre-defined euthanization criteria (such as significant weight loss or unresponsiveness to external stimuli) according to Institutional Animal Care and Use Committee-approved protocols. The investigators were not blinded to the outcome assessment.
Reporting Summary. Further information on experimental design is available in the Nature Research Reporting Summary linked to this article.
Data availability. The authors declare that all data supporting the findings of this study are available within the paper and its Supplementary Information. The data in the figures are available from the corresponding author upon request. Corresponding author(s): Andres J. Garcia
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